#8600. Ravidasvir: equitable access through an alternative drug development pathway

December 2026publication date
Proposal available till 30-05-2025
5 total number of authors per manuscript4030 $

The title of the journal is available only for the authors who have already paid for
Journal’s subject area:
Medicine (all);
Places in the authors’ list:
place 1place 2place 3place 4place 5
FreeFreeFreeFreeFree
980 $890 $810 $720 $630 $
Contract №8600.1 Contract №8600.2 Contract №8600.3 Contract №8600.4 Contract №8600.5
1 place - free (for sale)
2 place - free (for sale)
3 place - free (for sale)
4 place - free (for sale)
5 place - free (for sale)

Abstract:
Ravidasvir was successfully registered as a treatment for hepatitis C. Its development comes with specific challenges, however, which this review aims to discuss.
Keywords:
Ravidasvir; drug development pathway; direct-acting antivirals; high-income countries; affordability and public health priorities; collaboration with low- and middle-income countries

Contacts :
0